SPRB Spruce Biosciences
- 0.630
- -0.023-3.46%
- 0.625
- -0.006-0.87%
Spruce Biosciences News
Express News | Spruce Biosciences: Under Asset Purchase Agreement, Co to Acquire Transferred Assets From Eiger for $10.0 Mln Subject to Certain Circumstances
Express News | Spruce Biosciences : On June 17, an Auction Was Conducted With Respect to Transferred Assets as Part of Eiger's Court-Supervised Sale Process
Express News | Spruce Biosciences- Agreed to Buy All Rights,Title,Interests in,to & Under Some Assets,Interests Used by Eiger BioPharmaceuticals Related to Avexitide
Express News | Spruce Biosciences Inc: On June 13, Co Entered Into a "Stalking Horse" Asset Purchase Agreement
Oppenheimer Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Cuts Target Price to $3
Oppenheimer analyst Hartaj Singh maintains $Spruce Biosciences(SPRB.US)$ with a buy rating, and adjusts the target price from $4 to $3.According to TipRanks data, the analyst has a success rate of 43.
Spruce Biosciences Is Maintained at Outperform by Oppenheimer
Spruce Biosciences Is Maintained at Outperform by Oppenheimer
Express News | Spruce Biosciences : Oppenheimer Cuts Target Price to $3 From $4
Spruce Biosciences Recognized as a Bay Area Best Place to Work
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine an
H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Hold Rating
H.C. Wainwright analyst Ram Selvaraju maintains $Spruce Biosciences(SPRB.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 36.8% and a total average return of 3.5%
JMP Securities Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $3
JMP Securities analyst Jonathan Wolleben maintains $Spruce Biosciences(SPRB.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 4
Express News | Spruce Biosciences And HMNC Brain Health Collaborate To Develop Spruce's Investigational Product Candidate, Tildacerfont With HMNC's Companion Diagnostic For Major Depressive Disorder, HMNC To Initiate Phase 2 Study In Q4 2024
Express News | Spruce Biosciences Inc: Hmnc to Initiate Phase 2 Study for Treatment of Mdd in Q4 2024
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
Pairs Spruce's Investigational Product Candidate, Tildacerfont, with HMNC's Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF1 Receptor Antagonism Provides
Express News | Spruce Biosciences Presented Phase 2 Power Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at Endo 2024
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced
Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocri
Hold Rating on Spruce Biosciences Amid Clinical Trial Uncertainties and Rising Competition
Spruce Biosciences Faces Nasdaq Delisting Threat Over Low Stock Prices
Buy Rating Affirmed for Spruce Biosciences Amid Upcoming Trial Data and Strong Financial Position
Express News | HC Wainwright & Co. Reiterates Neutral on Spruce Biosciences
Analysis
Price Target
No Data
